Back
News Non classé
1 min de lecture

[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.

  • contact@xenothera.com
  • Auteur
    contact@xenothera.com
  • Publié
    21 décembre 2022

Articles récents

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

September 12, 2023. # Download our press release (english version) # Télécharger...

More

[Press Release] XENOTHERA strengthens its management team and governance. June 8, 2023.

June 8, 2023. # Download our press release (english version) # Télécharger...

More

[Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023.

May 30, 2023. # Download our press release (english version) # Télécharger...

More